INSIGHTS ON DRUG DEVELOPMENT

  • 6 Regulatory Changes Affecting Bioprocessing In China

    This article outlines six recent regulatory changes in China intended to protect patient safety as well as reduce regulatory burdens and minimize delays.

  • Key Considerations For A Successful EU Orphan Drug Launch

    During this interactive webinar, the speakers involved will utilize their experience to guide you through the EU product launch process, from submitting your Marketing Application (MA) to final distribution of drug product to the end-user.

  • A Plasma Problem: Dwindling Supply In The Face Of A Growing Demand

    An outlook on the market shows plasma fractionators will have to look to innovation and other opportunities for supply, in order to meet the needs of patients.

  • Integrated Tools For Upstream Process Intensification: Part II

    Changes to bioprocessing methodologies in the biopharmaceutical industry are being driven by the need for increased speed, a lower cost of goods (COGs) and greater flexibility. Faster development times are required to progress biologics and vaccines more rapidly into clinical development and then to market to improve worldwide accessibility. Continue reading in part 2 of this series how in order for intensified and continuous bioprocessing to deliver on these quality and productivity promises, there is a requirement for intelligently designed products.

DRUG DEVELOPMENT SOLUTIONS

  • Capsugel® Colorista®: Unleash Your Creativity

    All the colors you need, in one capsule.

    Capsugel® Colorista® technology can provide a shorter development time for your product, while offering flexibility to progress with technical development before the final commercial color decision is taken. 

  • CFS 1500™ Capsule Filling and Sealing Machine

    The CFS 1500™ is a capsule filling and sealing machine and is a part of the Lonza Engine™ equipment portfolio, which was created to support bioavailability enhancement, encapsulation and early-phase clinical development technologies. To learn more about its capabilities and specifications, download the brochure.

  • Surfactant Analysis Services

    Successful drug product development should integrate formulation, manufacturing process, primary packaging, device and delivery to the patient. Lonza’s Drug Product Services (DPS) offering delivers a holistic approach to DP development that anticipates and prevents problems early, and ensures the result is a product that is fit for purpose.

  • Particle Control In Biopharmaceuticals

    Successful drug product development should integrate formulation, manufacturing process, primary packaging, device and delivery to the patient. Lonza’s Drug Product Services (DPS) offering delivers a holistic approach to DP development that anticipates and prevents problems early, and ensures the result is a product that is fit for purpose.

  • Viral Therapy Contract Manufacturing Services: Relevant Industry Experience

    Lonza is committed to working closely with our customers to provide cost-effective and time-efficient solutions for their development and manufacturing needs. Read more about our complete service including process development, GMP manufacturing of drug substances, aseptic fill/finish of drug product, product release testing, regulatory support and cGMP storage and distribution.